Los Angeles Capital Management
UTHR icon

Los Angeles Capital Management’s United Therapeutics UTHR Stock Holding History

Los Angeles Capital Management’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$17.3M Sell
29,124
-13,386
-31% -$6.67M 0.07% 195
2025
Q4 		$19.3M Sell
42,510
-19,081
-31% -$8.89M 0.07% 178
2025
Q3 		$25.8M Sell
61,591
-48,683
-44% -$16.4M 0.09% 165
2025
Q2 		$31.7M Buy
110,274
+23,280
+27% +$6.96M 0.12% 137
2025
Q1 		$26.8M Sell
86,994
-16,603
-16% -$5.69M 0.12% 141
2024
Q4 		$36.6M Buy
103,597
+13,030
+14% +$4.79M 0.15% 129
2024
Q3 		$32.5M Sell
90,567
-8,761
-9% -$2.96M 0.13% 139
2024
Q2 		$31.6M Buy
99,328
+10,476
+12% +$2.77M 0.11% 139
2024
Q1 		$20.4M Buy
88,852
+15,447
+21% +$3.49M 0.07% 215
2023
Q4 		$16.1M Buy
73,405
+22,155
+43% +$5.11M 0.06% 216
2023
Q3 		$11.6M Buy
51,250
+44,820
+697% +$10.3M 0.05% 231
2023
Q2 		$1.42M Sell
6,430
-99,413
-94% -$22M 0.01% 564
2023
Q1 		$23.7M Buy
105,843
+3,587
+4% +$884K 0.11% 178
2022
Q4 		$28.4M Buy
102,256
+53,444
+109% +$13.5M 0.14% 154
2022
Q3 		$10.2M Buy
+48,812
New +$10.9M 0.05% 271
2021
Q2 		– Sell
-2,134
Closed -$357K – 1677
2021
Q1 		$357K Sell
2,134
-6,139
-74% -$1.02M ﹤0.01% 1370
2020
Q4 		$1.26M Buy
8,273
+125
+2% +$16.4K 0.01% 835
2020
Q3 		$823K Sell
8,148
-800
-9% -$87.8K ﹤0.01% 893
2020
Q2 		$1.08M Buy
8,948
+6,240
+230% +$702K 0.01% 814
2020
Q1 		$257K Buy
+2,708
New +$257K ﹤0.01% 1104
2019
Q2 		– Sell
-27,702
Closed -$3.25M – 1430
2019
Q1 		$3.25M Sell
27,702
-1,733
-6% -$202K 0.02% 517
2018
Q4 		$3.21M Hold
29,435
– – 0.02% 448
2018
Q3 		$3.76M Sell
29,435
-6,198
-17% -$767K 0.02% 503
2018
Q2 		$4.03M Sell
35,633
-110,710
-76% -$12.2M 0.02% 525
2018
Q1 		$16.4M Sell
146,343
-45,965
-24% -$5.84M 0.09% 244
2017
Q4 		$28.5M Buy
192,308
+155,520
+423% +$19.8M 0.16% 170
2017
Q3 		$4.31M Sell
36,788
-82,355
-69% -$10.5M 0.02% 458
2017
Q2 		$15.5M Sell
119,143
-143,257
-55% -$17.9M 0.1% 247
2017
Q1 		$35.5M Buy
262,400
+31,873
+14% +$4.83M 0.26% 110
2016
Q4 		$33.1M Buy
+230,527
New +$29.4M 0.26% 123
2016
Q2 		– Sell
-4,404
Closed -$491K – 1290
2016
Q1 		$491K Hold
4,404
– – ﹤0.01% 823
2015
Q4 		$690K Sell
4,404
-3,103
-41% -$452K 0.01% 767
2015
Q3 		$985K Buy
7,507
+1,790
+31% +$287K 0.01% 704
2015
Q2 		$994K Buy
5,717
+1,475
+35% +$265K 0.01% 738
2015
Q1 		$731K Buy
4,242
+40
+1% +$6.1K 0.01% 824
2014
Q4 		$544K Sell
4,202
-251,168
-98% -$32.4M 0.01% 813
2014
Q3 		$32.9M Buy
255,370
+142,906
+127% +$14.7M 0.4% 69
2014
Q2 		$9.95M Sell
112,464
-48,316
-30% -$4.65M 0.1% 250
2014
Q1 		$15.1M Buy
160,780
+55,424
+53% +$5.67M 0.17% 172
2013
Q4 		$11.9M Buy
105,356
+61
+0.1% +$5.5K 0.13% 213
2013
Q3 		$8.3M Buy
105,295
+7,422
+8% +$542K 0.1% 255
2013
Q2 		$6.44M Buy
+97,873
New +$6.3M 0.09% 249

Other funds holding UTHR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Los Angeles Capital Management's UTHR Position: Q1 2026 in Review

Los Angeles Capital Management reduced its United Therapeutics (UTHR) stake by 31% in Q1 2026, selling an estimated $6.67M and leaving 29,124 shares worth $17.3M. The position accounts for 0.07% of the portfolio, ranked #195.

Los Angeles Capital Management first reported a position in UTHR in Q2 2013 and has held it in 42 quarters since. The position peaked at $36.6M in Q4 2024. 850 funds tracked by Wall St. Rank hold UTHR as of Q1 2026.

  • Los Angeles Capital Management held 29,124 shares of United Therapeutics worth $17.3M as of Q1 2026.
  • Los Angeles Capital Management sold 13,386 United Therapeutics shares in Q1 2026, an estimated $6.67M.
  • United Therapeutics made up 0.07% of Los Angeles Capital Management's portfolio in Q1 2026, its #195 holding.
  • Los Angeles Capital Management first reported a position in United Therapeutics in Q2 2013 and has held it in 42 quarters since.
  • Los Angeles Capital Management's United Therapeutics position peaked at $36.6M in Q4 2024.
  • 850 funds tracked by Wall St. Rank held United Therapeutics as of Q1 2026.

Based on Los Angeles Capital Management's 13F filing for Q1 2026, filed 8 May 2026.